Advanced

Pancreatic cancer: Translational research aspects and clinical implications.

Ansari, Daniel LU ; Chen, Bi-Cheng; Dong, Lei; Zhou, Meng-Tao and Andersson, Roland LU (2012) In World Journal of Gastroenterology 18(13). p.1417-1424
Abstract
Despite improvements in surgical techniques and adjuvant chemotherapy, the overall mortality rates in pancreatic cancer have generally remained relatively unchanged and the 5-year survival rate is actually below 2%. This paper will address the importance of achieving an early diagnosis and identifying markers for prognosis and response to therapy such as genes, proteins, microRNAs or epigenetic modifications. However, there are still major hurdles when translating investigational biomarkers into routine clinical practice. Furthermore, novel ways of secondary screening in high-risk individuals, such as artificial neural networks and modern imaging, will be discussed. Drug resistance is ubiquitous in pancreatic cancer. Several mechanisms of... (More)
Despite improvements in surgical techniques and adjuvant chemotherapy, the overall mortality rates in pancreatic cancer have generally remained relatively unchanged and the 5-year survival rate is actually below 2%. This paper will address the importance of achieving an early diagnosis and identifying markers for prognosis and response to therapy such as genes, proteins, microRNAs or epigenetic modifications. However, there are still major hurdles when translating investigational biomarkers into routine clinical practice. Furthermore, novel ways of secondary screening in high-risk individuals, such as artificial neural networks and modern imaging, will be discussed. Drug resistance is ubiquitous in pancreatic cancer. Several mechanisms of drug resistance have already been revealed, including human equilibrative nucleoside transporter-1 status, multidrug resistance proteins, aberrant signaling pathways, microRNAs, stromal influence, epithelial-mesenchymal transition-type cells and recently the presence of cancer stem cells/cancer-initiating cells. These factors must be considered when developing more customized types of intervention ("personalized medicine"). In the future, multifunctional nanoparticles that combine a specific targeting agent, an imaging probe, a cell-penetrating agent, a biocompatible polymer and an anti-cancer drug may become valuable for the management of patients with pancreatic cancer. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
World Journal of Gastroenterology
volume
18
issue
13
pages
1417 - 1424
publisher
WJG Press
external identifiers
  • wos:000302501200001
  • pmid:22509073
  • scopus:84859336668
ISSN
1007-9327
DOI
10.3748/wjg.v18.i13.1417
language
English
LU publication?
yes
id
629e1e37-6d96-47aa-95a0-dd971119bb23 (old id 2519358)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/22509073?dopt=Abstract
date added to LUP
2012-05-06 17:33:11
date last changed
2017-06-11 04:39:15
@article{629e1e37-6d96-47aa-95a0-dd971119bb23,
  abstract     = {Despite improvements in surgical techniques and adjuvant chemotherapy, the overall mortality rates in pancreatic cancer have generally remained relatively unchanged and the 5-year survival rate is actually below 2%. This paper will address the importance of achieving an early diagnosis and identifying markers for prognosis and response to therapy such as genes, proteins, microRNAs or epigenetic modifications. However, there are still major hurdles when translating investigational biomarkers into routine clinical practice. Furthermore, novel ways of secondary screening in high-risk individuals, such as artificial neural networks and modern imaging, will be discussed. Drug resistance is ubiquitous in pancreatic cancer. Several mechanisms of drug resistance have already been revealed, including human equilibrative nucleoside transporter-1 status, multidrug resistance proteins, aberrant signaling pathways, microRNAs, stromal influence, epithelial-mesenchymal transition-type cells and recently the presence of cancer stem cells/cancer-initiating cells. These factors must be considered when developing more customized types of intervention ("personalized medicine"). In the future, multifunctional nanoparticles that combine a specific targeting agent, an imaging probe, a cell-penetrating agent, a biocompatible polymer and an anti-cancer drug may become valuable for the management of patients with pancreatic cancer.},
  author       = {Ansari, Daniel and Chen, Bi-Cheng and Dong, Lei and Zhou, Meng-Tao and Andersson, Roland},
  issn         = {1007-9327},
  language     = {eng},
  number       = {13},
  pages        = {1417--1424},
  publisher    = {WJG Press},
  series       = {World Journal of Gastroenterology},
  title        = {Pancreatic cancer: Translational research aspects and clinical implications.},
  url          = {http://dx.doi.org/10.3748/wjg.v18.i13.1417},
  volume       = {18},
  year         = {2012},
}